| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Tosufloxacin tosylate, formerly known as T-3262 and A-61827, is a potent fluoroquinolone antibiotic used to treat susceptible infections. It has a controversial safety profile in relation to other fluoroquinolones. It is associated with severe thrombocytopenia and nephritis, and hepatotoxicity. It is sold in Japan under the brand name Ozex.
| ln Vitro |
Tosifloxacin tosylate hydrate (T-3262) (0.05-3.13 μg/mL; 18 h) possesses antibacterial action that is effective against Streptococcus, Enterococcus, Bacteroides fragilis, Clostridium difficile, and Clostridium perfringens [2].
|
|---|---|
| ln Vivo |
Sufloxacin tosylate hydrate (T-3262) treatment (oral gavage; 0.16–13.39 mg/kg; once) showed antibacterial efficacy against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus in vivo [2].
|
| Cell Assay |
Cell Viability Assay[2]
Cell Types: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus, Enterococcus, Bacteroides fragilis, Clostridium difficile and Clostridium perfringens Tested Concentrations: 0.05-3.13 μg/mL Incubation Duration: 18 Hourly Experimental Results: Displays MIC90s (MIC 90) for Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus, and Enterococcus, ranging from 0.05 to 1.56 μg/mL. MIC90 values for Bacteroides fragilis, Clostridium difficile, and Clostridium perfringens were 1.56, 3.13 and 0.20 μg/mL respectively. |
| Animal Protocol |
Animal/Disease Models: Male Slc:ICR mice infected with Staphylococcus aureus [2]
Doses: 1.27-2.15 mg/kg Route of Administration: po (oral gavage); 1.27-2.15 mg/kg; primary Experimental Results:7 days after infection demonstrated 50 The % effective dose (ED50) is 1.62 mg/kg (body weight). The displayed MIC value is 0.0125 μg/mL. Animal/Disease Models: Male Slc:ICR mice infected with E. coli [2] Doses: 0.16-0.30 mg/kg Route of Administration: po (oral gavage); 0.16-0.30 mg/kg; Primary Experimental Results:50% effective 7 days after infection The dose (ED50) is 0.22 mg/kg (body weight). The displayed MIC value is 0.0125 μg/mL. Animal/Disease Models: Male Slc:ICR mice infected with Pseudomonas aeruginosa [2] Doses: 7.66-13.39 mg/kg Route of Administration: po (oral gavage); 7.66-13.39 mg/kg; Primary Experimental Results:Displayed 7 days after infection The 50% effective dose (ED50) is 10.13 mg/kg (body weight). The displayed MIC value is 0.78 μg/mL. |
| References |
[1]. Chu DT, et al. Synthesis and biological properties of A-71497: a prodrug of tosufloxacin. Drugs Exp Clin Res. 1990;16(9):435-43.
[2]. Fujimaki K, et al. In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone. Antimicrob Agents Chemother. 1988 Jun;32(6):827-33. |
| Molecular Formula |
C26H23F3N4O6S
|
|---|---|
| Molecular Weight |
576.54422
|
| Exact Mass |
404.11
|
| Elemental Analysis |
C, 54.16; H, 4.02; F, 9.89; N, 9.72; O, 16.65; S, 5.56
|
| CAS # |
115964-29-9
|
| Related CAS # |
Tosufloxacin tosylate hydrate;1400591-39-0;Tosufloxacin;100490-36-6
|
| Appearance |
Solid powder
|
| SMILES |
O=C(C1=CN(C2=CC=C(F)C=C2F)C3=NC(N4CC(N)CC4)=C(F)C=C3C1=O)O.OS(=O)(C5=CC=C(C)C=C5)=O
|
| InChi Key |
CSSQVOKOWWIUCX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H15F3N4O3.C7H8O3S/c20-9-1-2-15(13(21)5-9)26-8-12(19(28)29)16(27)11-6-14(22)18(24-17(11)26)25-4-3-10(23)7-251-6-2-4-7(5-3-6)11(8,9)10/h1-2,5-6,8,10H,3-4,7,23H2,(H,28,29)2-5H,1H3,(H,8,9,10)
|
| Chemical Name |
7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic
acid tosylate
|
| Synonyms |
T-3262 T3262 T 3262 Tosufloxacin tosylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7345 mL | 8.6724 mL | 17.3449 mL | |
| 5 mM | 0.3469 mL | 1.7345 mL | 3.4690 mL | |
| 10 mM | 0.1734 mL | 0.8672 mL | 1.7345 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA